Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer
Keywords:
cáncer, Diabetes Mellitus Type 2, older adults, EpidemiologyAbstract
Clinical and epidemiological evidence shows associations between cancer and type 2 diabetes mellitus (DM2). These diseases share some common pathophysiological mechanisms. Aim: To study in a population of older adults whether the presence of DM2 affects the epidemiological parameters of cancer.
Retrospective observational epidemiological study (2006-2017), analysis of 4,574 medical records of patients (≥65 years), Centro San Ricardo Pampuri (Va. Carlos Paz, Córdoba). Cancer patients were grouped: with DM2 and without DM2. The following were calculated and compared: prevalence, mortality, lethality and survival for each group. Data were analyzed with Infostat using ANOVA (continuous variables) and chi-square (categorical), p≤0.05. Confidentiality and anonymity were respected.
Population data: 56% women/44% men. 42% of the total population suffered from obesity and 39.8% DM2. 390 cancer patients in the period. General cancer prevalence=8.5%, mortality=27.5 ‰, lethality=32%. Average survival: 2544.44 days. Prevalences between patients with and without DM2, and between the sexes were similar, but higher in obese patients (58 vs 42%). Most frequent tumors: female: breast (0.44) and colon (0.10); male: prostate (0.36) and colon (0.17). Comparisons between patients with and without DM2: -Prevalence (‰): -Older in the group with DM2: Men: pancreas (1.31vs0.44), kidney (1.31vs0.44) and non-Hodgkin lymphoma (0.87vs0.44); Women: breast (11.15vs8.31), pancreas (1.75vs0) and endometrium (1.53vs0.87). -Higher in the group without DM2: Men: prostate (7vs4.37), colon (3.28vs2.84) and bladder (1.97vs0.87); Women: colon (3.06vs1.31), thyroid (1.09vs0.44) and melanoma (1.09vs0.22). –Age at diagnosis (years): colon cancer (68.91vs75.87) and prostate cancer (71.78vs77.74) were found at earlier ages in men with DM2. –Mortality: The values were similar in women with and without DM2 (RR:1.01; OR:1.02). In men it was lower for DM2 (RR:0.74; OR:0.57). Those with the highest mortality in patients with DM2 were: breast>colon>prostate>pancreas. –Lethality (%): higher in DM2 patients for gastric cancer (100vs50), while esophagus, colon, kidney and prostate were higher in the group without DM2. –Survival (days): women without DM2 have a higher survival (4213.5vs1802.73).
The existence of DM2 in comorbidity with cancer significantly affects the parameters studied, mainly in women, since breast cancer had a higher prevalence in women with DM2, and these had a lower survival.
Downloads
References
.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).